Time filter

Source Type

Weatherford, OK, United States

Southwestern Oklahoma State University is a public university in Weatherford and Sayre, Oklahoma. It is one of six Regional University System of Oklahoma members. SWOSU is placed at Tier 1 in the category "Regional Universities " in the 2011 U.S. News & World Report. SWOSU has 15 nationally accredited academic programs—the most among Oklahoma's senior regional universities. Wikipedia.

Bernhardt N.A.,Southwestern Oklahoma State University | Berhanu W.M.,University of Oklahoma | Hansmann U.H.E.,University of Oklahoma
Journal of Physical Chemistry B | Year: 2013

Seeding a protein solution with preformed fibrils can dramatically enhance the growth rate of amyloids. As the seeds do not need to be of the same protein, seeding may account for the observed correlations between amyloid diseases. In an effort to understand better the molecular mechanisms behind cross seeding we have studied in silico the effect of mutations on the seeding of amylin fibrils. Our investigations of the structural stability of decamers of wild type amylin peptides, of Y37L mutants, and of heteroassemblies of wild-type and mutant amylin molecules show that the experimentally observed efficient cross seeding can be explained based on similarity in fibril structure of components. We find that amyloids with similar side chains packing at the β-sheet interface are structurally compatible, acting as a good template for the congruent incorporation of homologues peptides. In the Y37L mutants, lack of tyrosine-specific interactions causes significant higher flexibility of the C terminal than observed in the wild-type fibril. This effects elongation of the mutant fibril leading to the longer lag times during aggregation that are observed in experiments. Our study gives guidelines for the design of ligands that could stabilize amylin fibrils. © 2013 American Chemical Society.

Williams N.T.,Southwestern Oklahoma State University
American Journal of Health-System Pharmacy | Year: 2010

Purpose. The pharmacology, uses, dosages, safety, drug interactions, and contrain-dications of probiotics are reviewed. Summary. Probiotics are live nonpathogenic microorganisms administered to improve microbial balance, particularly in the gastrointestinal tract. They consist of Saccharomyces boulardii yeast or lactic acid bacteria, such as Lactobacillus and Bifidobacterium species, and are regulated as dietary supplements and foods. Probiotics exert their beneficial effects through various mechanisms, including lowering intestinal pH, decreasing colonization and invasion by pathogenic organisms, and modifying the host immune response. Probiotic benefits associated with one species or strain do not necessarily hold true for others. The strongest evidence for the clinical effectiveness of probiotics has been in the treatment of acute diarrhea, most commonly due to rotavirus, and pouchitis. More research is needed to clarify the role of probiotics for preventing antibiotic-associated diarrhea, Clostridium difficile infection, travelers' diarrhea, irritable bowel syndrome, ulcerative colitis, Crohn's disease, and vulvovaginal candidiasis. There is no consensus about the minimum number of microorganisms that must be ingested to obtain a beneficial effect; however, a probiotic should typically contain several billion microorganisms to increase the chance that adequate gut colonization will occur. Probiotics are generally considered safe and well tolerated, with bloating and flatulence occurring most frequently. They should be used cautiously in patients who are critically ill or severely immunocompromised or those with central venous catheters since systemic infections may rarely occur. Bacteria-derived probiotics should be separated from antibiotics by at least two hours. Conclusion. Probiotics have demonstrated efficacy in preventing and treating various medical conditions, particularly those involving the gastrointestinal tract. Data supporting their role in other conditions are often conflicting. Copyright © 2010, American Society of Health-System Pharmacists, Inc. All rights reserved.

Pereira A.L.,Southwestern Oklahoma State University
IEEE International Symposium on Parallel and Distributed Processing Workshops and Phd Forum | Year: 2011

This paper describes a Role-based Access Control (RBAC) mechanism for distributed High Performance Computing (HPC) systems that will facilitate scalable evaluation, management and enforcement of access control policies. The RBAC mechanism forms an enhanced security framework for Grids and Clouds that will allow for interoperability between technologies in the two domains. The mechanisms being proposed here are important because the current lack of software tools and security standards in accessing distributed HPC systems and transporting Large Data Sets can add immensely to overheads in data processing or data integration times. RBAC models make policy management scalable and by virtue of being modular allow for more sophisticated access control models to be integrated with them. This paper shows how existing security standards can be leveraged for the specification and management of RBAC policies with the aim to allow disparate applications, systems and security domains to interoperate. The eXtensible Access Control Markup Language (XACML) can be used for policy specification and management across disparate organizations and the Security Assertion Markup Language (SAML) can be used for authentication and authorization assertions across the same. Both standards can be leveraged to facilitate policy management and enforcement, and delegation of rights. Authorization servers like Shibboleth can be leveraged for use as RBAC system components. © 2011 IEEE.

Asante J.N.,Southwestern Oklahoma State University
International Journal of Advanced Manufacturing Technology | Year: 2010

This paper computes and investigates the effect of fixture compliance and cutting conditions on workpiece stability and uses it as a basis for selecting a suitable fixture among several alternatives. We use two criteria, the minimum eigenvalue of the fixture stiffness matrix and the largest displacement of the workpiece due to the cutting forces to assess the stability of the workpiece. First, the minimum eigenvalues of the fixture stiffness matrices, for the fixtures being considered, are computed. Second, since the eigenvalues are not dependant on the cutting forces, a displacement measure, the largest displacement of the workpiece due to the cutting force, is computed for each fixture. This displacement is a function of the cutting force and the fixture compliance. The choice of fixture is often a compromise between the two criteria. We also consider the combined influence of fixture compliance and cutting conditions on workpiece stability. The results from the simple study used for illustration show that the eigenvalues remain constant under different cutting conditions whilst the largest displacement reduces by 68%, a significant reduction. © Springer-Verlag London Limited 2009.

Thompson D.F.,Southwestern Oklahoma State University | Brooks K.G.,Southwestern Oklahoma State University
Journal of Clinical Pharmacy and Therapeutics | Year: 2015

What is known and objective Neuropathic pain is a common disorder for which patients seek treatment. The most common causes of neuropathic pain are diabetes, herpetic infection and chemotherapy-induced neuropathy. Oral administration of amitriptyline has traditionally been used for treating neuropathic pain; however, it has dose-related anticholinergic effects, which may limit its use in some individuals. Pharmacotherapeutic agents that are commonly used to treat neuropathic pain include antidepressants, anticonvulsants, opioids and opioid-like substances, and topical medications. The objective of this paper is to review the effectiveness of topical amitriptyline in patients with neuropathic pain. Methods We utilized the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to provide a systematic and transparent reporting method. The literature search was performed using PubMed (1966 through October 2014) applying the MeSH 'amitriptyline' and 'drug administration, topical' and 'neuropathy'. Web of Science (1945 through October 2014) was searched using the text words 'amitriptyline' and 'neuropathy'. Bibliographies of retrieved articles were scanned for relevant articles. Cochrane databases were also searched for methods to treat neuropathic pain. Broad subject headings, including 'neuropathic pain', were used to search the database for review articles. All data sources in English and in humans were considered for inclusion. Results and discussion Topical application of amitriptyline has the theoretical advantage of local effects with fewer systemic side effects. The clinical trials and case reports describing the use of topical amitriptyline we reviewed show mixed results concerning the efficacy and the presence of adverse reactions. Controlled clinical trials reveal that topical amitriptyline is not effective in treating neuropathic pain. The uncontrolled clinical trials did support efficacy of topical amitriptyline; however, the data from these trials may be biased due to the nature of the study design. Finally, there have been several case reports that claim patients achieved pain relief with the use of topical amitriptyline. Data from these cases are limited due to the fact that there were no controls to which the amitriptyline treatments could be compared, and the majority of the patients in these cases were on other analgesics. What is new and conclusion Although there are reports that describe the benefits of topical amitriptyline for neuropathic pain, data from evidence-based controlled clinical trials do not support efficacy in patients who use topical amitriptyline for neuropathic pain control. Neuropathic pain is a common disorder for which patients seek treatment. The objective of this paper is to review the effectiveness of topical amitriptyline in patients with neuropathic pain. Although there are reports that describe the benefits of topical amitriptyline for neuropathic pain, data from evidence-based controlled clinical trials do not support efficacy in patients who use topical amitriptyline for neuropathic pain control. © 2015 John Wiley & Sons Ltd.

Discover hidden collaborations